Testing a PARP drug plus targeted radiation for bowel or pancreas tumors
Treatments studied
Part of Cancer clinical trials.
This Phase 1 study tests how safe and effective it is to combine a PARP inhibitor (a targeted cancer medicine) with PRRT, a treatment that delivers radiation directly to certain tumor cells. It is for people with grade 2 neuroendocrine tumors from the pancreas or intestines, especially when scans suggest the tumor will take up the targeted radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old and willing to sign consent for the study
- Your general health is fairly good (ECOG 0 to 2)
- Your tumor is a grade 2 neuroendocrine tumor from the pancreas or intestines, with Ki-67 between 3% and 20%
- Scans look right: GaTate PET/CT shows tumor uptake higher than the liver (Krenning score at least 3), and an FDG PET/CT scan does not show mismatched aggressive disease
- Your heart and organs can handle treatment: no major untreated “carcinoid heart” problems, and blood counts plus kidney and liver tests meet minimum levels
- You can follow the study plan (including medicines and scheduled visits) and you’re suitable for PRRT
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether adding a medicine called a PARP inhibitor to peptide receptor radionuclide therapy (PRRT) can better control advanced or metastatic neuroendocrine tumors (NET). It may help by targeting tumor DNA repair while PRRT delivers targeted radiation.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
This trial tests whether adding chemotherapy to a standard treatment (PRRT) works better than PRRT alone for people with certain types of digestive tract or pancreatic neuroendocrine tumors. It is for those whose tumors have higher activity on scans or are growing.
This trial tests if removing as much tumor as possible through surgery before a targeted radiation therapy (PRRT) can help people with well-differentiated neuroendocrine tumors that have spread to the liver. The goal is to see if this approach works better than radiation therapy alone.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.